According to Fortune Business Insights, the global Cell Therapy Market size was valued at USD 8.64 billion in 2025. The market is projected to grow from USD 12.22 billion in 2026 to USD 122.87 billion by 2034, exhibiting a CAGR of 33.14% during the forecast period (2026–2034). North America dominated the global cell therapy industry, accounting for 47.10% of the market share in 2025. Increasing demand for advanced cancer treatments, expanding regulatory approvals, and rising investments in regenerative medicine are supporting market growth.
Cell therapy represents an important advancement in modern medicine, particularly for patients with conditions that respond poorly to conventional treatments.
The industry includes chimeric antigen receptor T-cell (CAR-T) therapy, T-cell receptor (TCR-T) therapy, natural killer (NK) cell therapies, and other cellular treatments.
These therapies involve modifying or preparing living cells to improve their ability to recognize diseased cells, support immune responses, or restore normal biological functions.
Increasing regulatory approvals and growing investments in biotechnology are accelerating the commercialization of innovative cell-based therapies.
Major pharmaceutical companies are expanding their clinical pipelines and manufacturing capabilities to meet growing treatment demand.
For detailed market insights: https://www.fortunebusinessinsights.com/cell-therapy-market-114224
One of the most significant cell therapy market trends is the development of treatments targeting solid tumors.
Manufacturers are investigating engineered T-cells capable of recognizing multiple antigens, potentially improving treatment effectiveness and reducing tumor escape.
In February 2024, the U.S. FDA approved AMTAGVI (lifileucel), developed by Iovance Biotherapeutics, for advanced melanoma.
Allogeneic therapies use donor-derived cells and offer opportunities for ready-to-use treatments.
These approaches may reduce manufacturing delays and improve scalability compared with individualized autologous therapies.
Biopharmaceutical companies are expanding research facilities and specialized manufacturing infrastructure to support cell therapy commercialization.
Advancements in genetic engineering and cellular modification are encouraging development of therapies tailored to specific disease characteristics.